Core Insights - Beijing Zhongke Gene Technology Co., Ltd. (Zhongke Gene) has disclosed its progress report on the guidance for its initial public offering (IPO) [2] - The guidance agreement with Guotai Junan was signed in March 2021, with the guidance period set from July 2025 to September 2025 [2] Company Overview - Zhongke Gene was established on April 22, 2016, and specializes in third-party veterinary testing services, veterinary diagnostic products, and related biological materials [2] - The company is one of the first independent third-party veterinary testing laboratories in China to obtain CMA certification [2] - The registered capital of Zhongke Gene is 93.2819 million yuan [2] Ownership Structure - The actual controller of Zhongke Gene is Zhang Xuke, who holds a total shareholding ratio of 35.58% and a voting power of 78.48% [2] - Other shareholders include PlaiKe, CITIC Agriculture, Da'an Gene, and Wantai Biological Pharmacy [2] Leadership Profile - Zhang Xuke has a bachelor's degree and is a researcher with special government allowances [4] - He has held various positions, including veterinarian at the Luoyang Railway Veterinary Quarantine Station and executive director at Luoyang PlaiKe Biological Engineering Co., Ltd. [4] - Currently, he serves as the chairman of the fifth board of directors of PlaiKe and holds several leadership roles in veterinary associations [4]